Literature DB >> 31895616

Reply to N. Hanna et al and L. Xie et al.

Suresh S Ramalingam1, Suzanne E Dahlberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31895616      PMCID： PMC7048159          DOI： 10.1200/JCO.19.02741

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.

Authors:  Suresh S Ramalingam; Suzanne E Dahlberg; Chandra P Belani; Joel N Saltzman; Nathan A Pennell; Gopakumar S Nambudiri; John C McCann; Jerome D Winegarden; Mohammed A Kassem; Mohamed K Mohamed; Jan M Rothman; Alan P Lyss; Leora Horn; Thomas E Stinchcombe; Joan H Schiller
Journal:  J Clin Oncol       Date:  2019-07-30       Impact factor: 44.544

2.  The Case for Maintenance Pemetrexed Plus Bevacizumab.

Authors:  Nasser Hanna; Shadia Jalal
Journal:  J Clin Oncol       Date:  2020-01-02       Impact factor: 44.544

3.  Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: More Questions Than Answers.

Authors:  Li Xie; Xingwen Fan; Biyun Qian
Journal:  J Clin Oncol       Date:  2020-01-02       Impact factor: 44.544

4.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

5.  Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.

Authors:  F Barlesi; A Scherpereel; V Gorbunova; R Gervais; A Vikström; C Chouaid; A Chella; J H Kim; M J Ahn; M Reck; A Pazzola; H T Kim; J G Aerts; C Morando; A Loundou; H J M Groen; A Rittmeyer
Journal:  Ann Oncol       Date:  2014-02-27       Impact factor: 32.976

6.  Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.

Authors:  Panos M Fidias; Shaker R Dakhil; Alan P Lyss; David M Loesch; David M Waterhouse; Jane L Bromund; Ruqin Chen; Maria Hristova-Kazmierski; Joseph Treat; Coleman K Obasaju; Martin Marciniak; John Gill; Joan H Schiller
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.

Authors:  Jyoti D Patel; Thomas A Hensing; Alfred Rademaker; Eric M Hart; Matthew G Blum; Daniel T Milton; Philip D Bonomi
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.